Novartis to slice 500 jobs from UK facility

Novartis plans to shed around 500 jobs at its Horsham R&D and manufacturing site in southern England, dealing a fresh blow to Britain's pharma jobs base just six weeks after Pfizer unveiled a major site closure. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.